Segmented Insulin Polypeptides for Diabetes Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diabetes treatments, primarily relying on insulin and other pharmaceutical agents, have limited efficiency and are associated with significant side effects, necessitating the development of a substance that can effectively modulate blood sugar levels with fewer adverse effects.
Innovation Solution
A novel polypeptide with specific amino acid sequences, capable of binding to insulin receptors, is developed to reduce blood sugar levels, glycated hemoglobin, and alleviate hepato-renal disorders caused by diabetes, offering a more efficient and safer treatment option.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If insulin and pharmaceutical agents are used to treat diabetes, then blood sugar levels can be reduced, but significant side effects occur
Solution Approach 1:
The patent segments the insulin molecule into smaller peptide fragments (such as the B-chain segments B1-B20, B1-B15, B1-B10, and B1-B7). These segmented peptides retain the ability to bind to insulin receptors and reduce blood sugar while having reduced immunogenicity and fewer side effects compared to complete insulin molecules.
Solution Approach 2:
The patent extracts specific functional segments from the insulin molecule, particularly the B-chain segments containing the receptor-binding domain. By isolating and utilizing only the essential functional portions (such as B1-B7 or B1-B10 segments), the invention achieves blood sugar reduction efficacy while eliminating unnecessary portions that contribute to side effects.
2Quantity of substance
If conventional diabetes medications are used, then blood sugar can be controlled, but liver and kidney disorders may worsen
Solution Approach 1:
The patent changes the molecular parameters of the insulin by using truncated peptide sequences with fewer amino acids (e.g., B1-B7 has only 7 amino acids compared to the full insulin B-chain of 30 amino acids). This parameter change results in peptides that are more rapidly cleared by the kidneys, reducing accumulation and toxicity in hepato-renal systems while maintaining glucose-lowering efficacy.
3Quantity of substance
If insulin therapy is applied, then diabetes symptoms are treated, but the efficiency is limited due to multifactorial causes of diabetes
Solution Approach 1:
The patent designs peptide segments that can serve multiple functions: they can bind to insulin receptors to stimulate glucose uptake, act as insulin sensitizers to improve insulin resistance, and potentially activate other metabolic pathways. This multi-functionality addresses the multifactorial nature of diabetes (insulin deficiency, insulin resistance, and metabolic abnormalities) more comprehensively than conventional insulin therapy alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively binds to insulin receptors, triggering autophosphorylation and enhancing insulin signal transduction, thereby reducing blood sugar levels and improving hepato-renal disorders, providing a safer and more flexible treatment approach compared to existing methods.
Implementation Method 1
triggering autophosphorylation and enhancing insulin signal transduction
Data Source
AI summary
A polypeptide, a nucleic acid molecule encoding the polypeptide and a pharmaceutical composition comprising the polypeptide are provided. The polypeptide is as defined in the description, can bind to insulin receptors, and is effective in reducing blood sugar, reducing glycated hemoglobin, and ameliorating hepato-renal disorders caused by diabetes.